Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats - 29/08/11
Reprint requests: H. J. Verkade, MD, PhD, Center for Liver, Intestine, and Metabolic Diseases, Pediatric Gastroenterology, Department of Pediatrics, CMC IV, Room Y2.115, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.Abstract |
Objective |
To determine whether serum levels of unconjugated bilirubin (UCB) can be decreased by enhancing fecal fat excretion.
Study design |
Gunn rats were fed a high-fat diet (control) or the same diet mixed with the lipase inhibitor orlistat. At regular intervals, plasma UCB concentrations were determined and 72-hour fat balances were performed.
Results |
Orlistat treatment decreased plasma UCB concentrations (at 3 weeks; 100 mg/kg, −33%±8%, P<.05; 200 mg/kg, −46%±10%, P<.01). Within days of treatment, orlistat treatment increased fecal excretion of UCB (at day 3; +220%, P<.05). During 24 weeks of orlistat treatment (200 mg/kg diet), the plasma bilirubin concentrations were continuously ≈35% lower than in control rats. Plasma UCB concentrations were inversely correlated with the amount of fecal fat excretion (n=12, r=−0.87, P<.001).
Conclusions |
In Gunn rats, orlistat treatment increases the fecal excretion of fat and enhances the disposal of UCB. This approach could lead to novel strategies for prevention and treatment of unconjugated hyperbilirubinemia in patients.
Le texte complet de cet article est disponible en PDF.Abbreviations : UCB
Plan
 | Supported by a NUFFIC grant (Tomoji Nishioka). Henkjan Verkade is a Fellow of the Royal Netherlands Academy of Arts and Sciences. |
Vol 143 - N° 3
P. 327-334 - septembre 2003 Retour au numéro
Article précédent
- Observations related to neonatal hypoglycemia
- Robert P. Schwartz
- MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency
- Ute Spiekerkoetter, Bin Sun, Thomas Zytkovicz, Ronald Wanders, Arnold W. Strauss, Udo Wendel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?